A Phase II Study of Intensity-Modulated Radiation Therapy for the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer

Protocol
13-070
Full Title
A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Phase
II
Purpose

The standard treatment for non-anaplastic non-medullary thyroid cancer is radiation delivered through a liquid or capsules containing radioactive iodine. Some patients also undergo surgery. Yet sometimes the cancer persists.

In this study, researchers are evaluating a form of external radiation therapy called intensity-modulated radiation therapy (IMRT) for patients with non-anaplastic non-medullary thyroid cancers that persist despite radioactive iodine treatment and surgery, or for whom surgery is not an option. With IMRT, patients receive highly customized radiation beams of different intensities delivered from different angles to target cancerous tissue precisely, sparing nearby healthy tissue from damage.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have non-anaplastic non-medullary thyroid cancer that has persisted despite radioactive iodine treatment.
  • Patients should have had surgery or have a cancer that cannot be surgically removed.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Nancy Lee at 212-639-3341.

Disease(s)
Head & Neck Cancer
Thyroid Cancer